dc.contributor.author | Efe, C. | |
dc.contributor.author | Lammert, C. | |
dc.contributor.author | Taşçılar, K. | |
dc.contributor.author | Dhanasekaran, R. | |
dc.contributor.author | Ebik, B. | |
dc.contributor.author | Higuera-de la Tijera, F. | |
dc.contributor.author | Calışkan, A.R. | |
dc.contributor.author | Peralta, M. | |
dc.contributor.author | Gerussi, A. | |
dc.contributor.author | Massoumi, H. | |
dc.contributor.author | Catana, A.M. | |
dc.contributor.author | Purnak, T. | |
dc.contributor.author | Rigamonti, C. | |
dc.contributor.author | Aldana, A.J.G. | |
dc.contributor.author | Khakoo, N. | |
dc.contributor.author | Nazal, L. | |
dc.contributor.author | Frager, S. | |
dc.contributor.author | Demir, N. | |
dc.contributor.author | Irak, K. | |
dc.contributor.author | Melekoğlu-Ellik, Z. | |
dc.contributor.author | Kacmaz, H. | |
dc.contributor.author | Balaban, Y. | |
dc.contributor.author | Atay, K. | |
dc.contributor.author | Eren, F. | |
dc.contributor.author | Alvares-da-Silva, M.R. | |
dc.contributor.author | Cristoferi, L. | |
dc.contributor.author | Urzua, Á. | |
dc.contributor.author | Eşkazan, T. | |
dc.contributor.author | Magro, B. | |
dc.contributor.author | Snijders, R. | |
dc.contributor.author | Barutçu, S. | |
dc.contributor.author | Lytvyak, E. | |
dc.contributor.author | Zazueta, G.M. | |
dc.contributor.author | Demirezer-Bolat, A. | |
dc.contributor.author | Aydın, M. | |
dc.contributor.author | Heurgue-Berlot, A. | |
dc.contributor.author | De Martin, E. | |
dc.contributor.author | Ekin, N. | |
dc.contributor.author | Yıldırım, S. | |
dc.contributor.author | Yavuz, A. | |
dc.contributor.author | Bıyık, M. | |
dc.contributor.author | Narro, G.C. | |
dc.contributor.author | Kıyıcı, M. | |
dc.contributor.author | Akyıldız, M. | |
dc.contributor.author | Kahramanoğlu-Aksoy, E. | |
dc.contributor.author | Vincent, M. | |
dc.contributor.author | Carr, R.M. | |
dc.contributor.author | Günşar, F. | |
dc.contributor.author | Reyes, E.C. | |
dc.contributor.author | Harputluoğlu, M. | |
dc.contributor.author | Aloman, C. | |
dc.contributor.author | Gatselis, N.K. | |
dc.contributor.author | Üstündağ, Y. | |
dc.contributor.author | Brahm, J. | |
dc.contributor.author | Vargas, N.C.E. | |
dc.contributor.author | Güzelbulut, F. | |
dc.contributor.author | Garcia, S.R. | |
dc.contributor.author | Aguirre, J. | |
dc.contributor.author | Anders, M. | |
dc.contributor.author | Ratusnu, N. | |
dc.contributor.author | Hatemi, I. | |
dc.contributor.author | Mendizabal, M. | |
dc.contributor.author | Floreani, A. | |
dc.contributor.author | Fagiuoli, S. | |
dc.contributor.author | Silva, M. | |
dc.contributor.author | Idilman, R. | |
dc.contributor.author | Satapathy, S.K. | |
dc.contributor.author | Silveira, M. | |
dc.contributor.author | Drenth, J.P.H. | |
dc.contributor.author | Dalekos, G.N. | |
dc.contributor.author | N.Assis, D. | |
dc.contributor.author | Björnsson, E. | |
dc.contributor.author | Boyer, J.L. | |
dc.contributor.author | Yoshida, E.M. | |
dc.contributor.author | Invernizzi, P. | |
dc.contributor.author | Levy, C. | |
dc.contributor.author | Montano-Loza, A.J. | |
dc.contributor.author | Schiano, T.D. | |
dc.contributor.author | Ridruejo, E. | |
dc.contributor.author | Wahlin, S. | |
dc.date.accessioned | 2022-10-06T12:54:33Z | |
dc.date.available | 2022-10-06T12:54:33Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 14783223 (ISSN) | |
dc.identifier.uri | http://hdl.handle.net/11616/72300 | |
dc.description.abstract | Background: We investigated associations between baseline use of immunosuppressive drugs and severity of Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis (AIH). Patients and methods: Data of AIH patients with laboratory confirmed COVID-19 were retrospectively collected from 15 countries. The outcomes of AIH patients who were on immunosuppression at the time of COVID-19 were compared to patients who were not on AIH medication. The clinical courses of COVID-19 were classified as (i)-no hospitalization, (ii)-hospitalization without oxygen supplementation, (iii)-hospitalization with oxygen supplementation by nasal cannula or mask, (iv)-intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v)-ICU admission with invasive mechanical ventilation or (vi)-death and analysed using ordinal logistic regression. Results: We included 254 AIH patients (79.5%, female) with a median age of 50 (range, 17-85) years. At the onset of COVID-19, 234 patients (92.1%) were on treatment with glucocorticoids (n = 156), thiopurines (n = 151), mycophenolate mofetil (n = 22) or tacrolimus (n = 16), alone or in combinations. Overall, 94 (37%) patients were hospitalized and 18 (7.1%) patients died. Use of systemic glucocorticoids (adjusted odds ratio [aOR] 4.73, 95% CI 1.12-25.89) and thiopurines (aOR 4.78, 95% CI 1.33-23.50) for AIH was associated with worse COVID-19 severity, after adjusting for age-sex, comorbidities and presence of cirrhosis. Baseline treatment with mycophenolate mofetil (aOR 3.56, 95% CI 0.76-20.56) and tacrolimus (aOR 4.09, 95% CI 0.69-27.00) were also associated with more severe COVID-19 courses in a smaller subset of treated patients. Conclusion: Baseline treatment with systemic glucocorticoids or thiopurines prior to the onset of COVID-19 was significantly associated with COVID-19 severity in patients with AIH. © 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | |
dc.source | Liver International | |
dc.title | Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis |
Dosyalar | Boyut | Biçim | Göster |
---|---|---|---|
Bu öğe ile ilişkili dosya yok. |